0.60 USD
▲-0.02+0.27%
盘后 0.61 +1.52%
2026-08-03
市值
$7.42M
市盈率
—
EPS
-1.37
股息率
—
52 周区间
0.55 – 1.83
成交量
67.90K
Beta
1.56
目标价
4.30
52W 低 0.5552W 高 1.83
价格走势
公司简介
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in ...